[M03AB01, succinylcholine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Succinylcholine.]
[N05AL01, sulpiride, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Sulpiride.]
[N03AX03, sulthiame, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Sulthiame.]
[N05CD07, temazepam, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Temazepam.]
[S01HA03, tetracaine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Tetracaine.]
[N05AE05, lurasidone, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Lurasidone.]
[A04AD10, dronabinol, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Dronabinol.]
[N04BC07, apomorphine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Apomorphine.]
[L04AX02, thalidomide, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[R03DA07, theobromine, The therapeutic efficacy of Theobromine can be decreased when used in combination with Tapentadol.]
[R06AD03, thiethylperazine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Thiethylperazine.]
[N05CA19, thiopental, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Thiopental.]
[N05AB08, thioproperazine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Thioproperazine.]
[N05AC02, thioridazine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Thioridazine.]
[N05AF04, thiothixene, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Thiothixene.]
[N05AL03, tiapride, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Tiapride.]
[N02AX01, tilidine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Tilidine.]
[M03BX04, tolperisone, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Tolperisone.]
[N02AX02, tramadol, The risk or severity of serotonin syndrome can be increased when Tapentadol is combined with Tramadol.]
[N06AF04, tranylcypromine, The risk or severity of adverse effects can be increased when Tapentadol is combined with Tranylcypromine.]
[N06AX05, trazodone, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Trazodone.]
[C03DB02, triamterene, The therapeutic efficacy of Triamterene can be decreased when used in combination with Tapentadol.]
[N05CD05, triazolam, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Triazolam.]
[C03AA06, trichlormethiazide, The therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Tapentadol.]
[A03AB12, mepenzolate, The risk or severity of adverse effects can be increased when Mepenzolate is combined with Tapentadol.]
[N05AB06, trifluoperazine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Trifluoperazine.]
[N05AD02, trifluperidol, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Trifluperidol.]
[N05AA05, triflupromazine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Triflupromazine.]
[N04AA01, trihexyphenidyl, The risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Tapentadol.]
[A03AA05, trimebutine, The risk or severity of adverse effects can be increased when Trimebutine is combined with Tapentadol.]
[R06AD01, trimeprazine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Alimemazine.]
[N03AC02, trimethadione, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Trimethadione.]
[C02BA01, trimethaphan, The risk or severity of adverse effects can be increased when Trimethaphan is combined with Tapentadol.]
[N06AA06, trimipramine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Trimipramine.]
[R06AX07, triprolidine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Triprolidine.]
[A03BB01, butylscopolamine, The risk or severity of adverse effects can be increased when Butylscopolamine is combined with Tapentadol.]
[N06AX24, vilazodone, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Vilazodone.]
[N06AX02, tryptophan, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Tryptophan.]
[M03AA02, tubocurarine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Tubocurarine.]
[N03AX21, ezogabine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Ezogabine.]
[B01AC24, ticagrelor, Tapentadol can cause a decrease in the absorption of Ticagrelor resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N06AX09, viloxazine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Viloxazine.]
[B01AA03, warfarin, The risk or severity of adverse effects can be increased when Tapentadol is combined with Warfarin.]
[C03BA10, xipamide, The therapeutic efficacy of Xipamide can be decreased when used in combination with Tapentadol.]
[N05AF05, zuclopenthixol, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Zuclopenthixol.]
[N03AX14, levetiracetam, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Levetiracetam.]
[N05AE04, ziprasidone, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Ziprasidone.]
[G03AC10, drospirenone, The therapeutic efficacy of Drospirenone can be decreased when used in combination with Tapentadol.]
[G04BD07, tolterodine, The risk or severity of adverse effects can be increased when Tolterodine is combined with Tapentadol.]
[M03AC04, atracurium, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Atracurium.]
[S01FA01, atropine, The risk or severity of adverse effects can be increased when Atropine is combined with Tapentadol.]
[M03BX01, baclofen, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Baclofen.]
[A08AA11, lorcaserin, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Lorcaserin.]
[A06AX04, linaclotide, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Tapentadol.]
[L01EX05, regorafenib, The metabolism of Tapentadol can be decreased when combined with Regorafenib.]
[N05CA04, barbital, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Barbital.]
[S01GA07, brimonidine, Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Tapentadol.]
[N04BD02, rasagiline, The risk or severity of adverse effects can be increased when Tapentadol is combined with Rasagiline.]
[A03FA09, mosapride, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Mosapride.]
[N06DA02, donepezil, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Donepezil.]
[N03AX22, perampanel, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Perampanel.]
[N02CC03, zolmitriptan, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Zolmitriptan.]
[R06AC06, thonzylamine, The risk or severity of adverse effects can be increased when Thonzylamine is combined with Tapentadol.]
[G04BD10, darifenacin, The risk or severity of adverse effects can be increased when Darifenacin is combined with Tapentadol.]
[N01AA01, ethyl ether, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Diethyl ether.]
[C03AA01, bendroflumethiazide, The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Tapentadol.]
[L04AX06, pomalidomide, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Pomalidomide.]
[N05AD07, benperidol, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Benperidol.]
[A10BK02, canagliflozin, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Tapentadol.]
[A06AX06, tegaserod, The risk or severity of serotonin syndrome can be increased when Tegaserod is combined with Tapentadol.]
[R02AD01, benzocaine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Benzocaine.]
[N02CC02, naratriptan, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Naratriptan.]
[N04AC01, benztropine, The risk or severity of adverse effects can be increased when Benzatropine is combined with Tapentadol.]
[P03AX06, benzyl alcohol, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Benzyl alcohol.]
[N06AX28, levomilnacipran, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Levomilnacipran.]
[N06AX26, vortioxetine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Vortioxetine.]
[N03AF04, eslicarbazepine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Eslicarbazepine.]
[N03AG04, vigabatrin, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Vigabatrin.]
[A10BK01, dapagliflozin, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Tapentadol.]
[N05CH03, tasimelteon, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Tasimelteon.]
[A03BA03, hyoscyamine, The risk or severity of adverse effects can be increased when Hyoscyamine is combined with Tapentadol.]
[B01AA07, acenocoumarol, The risk or severity of adverse effects can be increased when Tapentadol is combined with Acenocoumarol.]
[N01AX05, alfaxalone, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Alfaxalone.]
[D11AA01, glycopyrronium, The risk or severity of adverse effects can be increased when Glycopyrronium is combined with Tapentadol.]
[N05CM19, suvorexant, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.]
[N05AA04, acepromazine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Acepromazine.]
[A06AB04, phenolphthalein, The therapeutic efficacy of Phenolphthalein can be decreased when used in combination with Tapentadol.]
[A06AH03, naloxegol, The risk or severity of adverse effects can be increased when Tapentadol is combined with Naloxegol.]
[N04AA02, biperiden, The risk or severity of adverse effects can be increased when Biperiden is combined with Tapentadol.]
[A06AG02, bisacodyl, The therapeutic efficacy of Bisacodyl can be decreased when used in combination with Tapentadol.]
[B01AA01, dicumarol, The risk or severity of adverse effects can be increased when Tapentadol is combined with Dicoumarol.]
[N06AX11, mirtazapine, Tapentadol may increase the serotonergic activities of Mirtazapine.]
[A03AA09, difemerine, The risk or severity of adverse effects can be increased when Difemerine is combined with Tapentadol.]
[B01AA11, tioclomarol, The risk or severity of adverse effects can be increased when Tapentadol is combined with Tioclomarol.]
[A07DA06, eluxadoline, The risk or severity of constipation can be increased when Tapentadol is combined with Eluxadoline.]
[N05AX16, brexpiprazole, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Brexpiprazole.]
[G02CX02, flibanserin, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Flibanserin.]
[A06AD03, magnesium peroxide, The therapeutic efficacy of Magnesium peroxide can be decreased when used in combination with Tapentadol.]
[N05AX15, cariprazine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Cariprazine.]
[S01EC01, acetazolamide, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Acetazolamide.]
[N05AB07, acetophenazine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Acetophenazine.]
[J02AC05, isavuconazole, The metabolism of Tapentadol can be decreased when combined with Isavuconazole.]
[N05CA05, aprobarbital, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Aprobarbital.]
[N03AX23, brivaracetam, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Brivaracetam.]
[N05BA08, bromazepam, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Bromazepam.]
[N04BC01, bromocriptine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Bromocriptine.]
[A03AX08, alverine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Alverine.]
[R06AB01, brompheniramine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Dexbrompheniramine.]
[N06AA19, amineptin, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Amineptine.]
[N06BX11, aniracetam, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Aniracetam.]
[C03CA02, bumetanide, The therapeutic efficacy of Bumetanide can be decreased when used in combination with Tapentadol.]
[N01BB01, bupivacaine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Bupivacaine.]
[N07BC01, buprenorphine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N05BE01, buspirone, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Buspirone.]
[N02AF01, butorphanol, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Butorphanol.]
[S01GX07, azelastine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.]
[A06AX07, plecanatide, The therapeutic efficacy of Plecanatide can be decreased when used in combination with Tapentadol.]
[A06AH05, naldemedine, The therapeutic efficacy of Tapentadol can be decreased when used in combination with Naldemedine.]
[N02BF02, pregabalin, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Pregabalin.]
[N03AX30, beclamide, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Beclamide.]
[S01HA02, benoxinate, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Oxybuprocaine.]
[J01XX08, linezolid, The risk or severity of adverse effects can be increased when Tapentadol is combined with Linezolid.]
[N04BD03, safinamide, The risk or severity of adverse effects can be increased when Tapentadol is combined with Safinamide.]
[J05AG03, efavirenz, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Efavirenz.]
[N04AA11, bornaprine, The risk or severity of adverse effects can be increased when Bornaprine is combined with Tapentadol.]
[N05AD06, bromperidol, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Bromperidol.]
[N05CD09, brotizolam, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Brotizolam.]
[C03DA03, canrenone, The therapeutic efficacy of Canrenone can be decreased when used in combination with Tapentadol.]
[N05CA03, butobarbital, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Butobarbital.]
[N06AA15, butriptyline, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Butriptyline.]
[A10BK04, ertugliflozin, The therapeutic efficacy of Ertugliflozin can be decreased when used in combination with Tapentadol.]
[N05CA08, butylvinal, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Vinylbital.]
[N03AF01, carbamazepine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Carbamazepine.]
[A06AC08, calcium polycarbophil, The therapeutic efficacy of Calcium polycarbophil can be decreased when used in combination with Tapentadol.]
[A03AA03, camylofine, The risk or severity of adverse effects can be increased when Camylofin is combined with Tapentadol.]
[R06AA08, carbinoxamine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Carbinoxamine.]
[N03AX24, cannabidiol, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Cannabidiol.]
[N03AX17, stiripentol, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Stiripentol.]
[S01GX12, cetirizine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Cetirizine.]
[N05CM04, carbromal, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Carbromal.]
[N01BA04, chloroprocaine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Chloroprocaine.]
[R06AA06, chlorphenoxamine, The risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Tapentadol.]
[M03BA02, carisoprodol, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Carisoprodol.]
[R03BB08, revefenacin, The risk or severity of adverse effects can be increased when Revefenacin is combined with Tapentadol.]
[L01EX13, gilteritinib, The therapeutic efficacy of Tapentadol can be decreased when used in combination with Gilteritinib.]
[A06AX05, prucalopride, The therapeutic efficacy of Prucalopride can be decreased when used in combination with Tapentadol.]
[A03FA08, cinitapride, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Cinitapride.]
[N06AX27, esketamine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Esketamine.]
[N06BA14, solriamfetol, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Solriamfetol.]
[N06AX29, brexanolone, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Brexanolone.]
[N05BA09, clobazam, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Clobazam.]
[A06AB05, castor oil, The therapeutic efficacy of Castor oil can be decreased when used in combination with Tapentadol.]
[N05BA22, cloxazolam, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Cloxazolam.]
[N05AA06, cyamemazine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Cyamemazine.]
[C03BX03, cicletanine, The therapeutic efficacy of Cicletanine can be decreased when used in combination with Tapentadol.]
[M03BX08, cyclobenzaprine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Cyclobenzaprine.]
[C03AA09, cyclothiazide, The therapeutic efficacy of Cyclothiazide can be decreased when used in combination with Tapentadol.]
[G04BE04, yohimbine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Yohimbine.]
[A06AB03, danthron, The therapeutic efficacy of Dantron can be decreased when used in combination with Tapentadol.]
[N02CC08, lasmiditan, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Lasmiditan.]
[R06AB06, dexbrompheniramine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Dexbrompheniramine.]
[N02AX03, dezocine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Dezocine.]
[N05CM21, lemborexant, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Lemborexant.]
[N05AD10, lumateperone, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Lumateperone.]
[N02CC07, frovatriptan, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Frovatriptan.]
[N05CC04, dichloralphenazone, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Dichloralphenazone.]
[A07DA04, difenoxin, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Difenoxin.]
[N02AA08, dihydrocodeine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Dihydrocodeine.]
[N02CC06, eletriptan, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Eletriptan.]
[N03AG02, dipropylacetamide, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Valpromide.]
[N05BA02, chlordiazepoxide, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Chlordiazepoxide.]
[A03AA08, dihexyverine, The risk or severity of adverse effects can be increased when Dihexyverine is combined with Tapentadol.]
[G04BD09, trospium, The risk or severity of adverse effects can be increased when Trospium is combined with Tapentadol.]
[N05CM02, chlormethiazole, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Clomethiazole.]
[M03BB02, chlormezanone, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Chlormezanone.]
[R02AD04, dyclonine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Dyclonine.]
[N05CD14, remimazolam, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Remimazolam.]
[N02AX07, oliceridine, The risk or severity of hypotension, sedation, death, somnolence, and respiratory depression can be increased when Tapentadol is combined with Oliceridine.]
[C03AA04, chlorothiazide, The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Tapentadol.]
[R06AB04, chlorpheniramine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Chlorpheniramine.]
[N05AA01, chlorpromazine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Chlorpromazine.]
[N05AF03, chlorprothixene, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Chlorprothixene.]
[C03BA04, chlorthalidone, The therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Tapentadol.]
[M03BB03, chlorzoxazone, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Chlorzoxazone.]
[N05BX03, etifoxine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Etifoxine.]
[N06BX18, vinpocetine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Vinpocetine.]
[N05BA18, ethyl loflazepate, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Ethyl loflazepate.]
[M03BA05, febarbamate, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Febarbamate.]
[N03AX10, felbamate, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Felbamate.]
[N01AB05, trichloroethylene, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Trichloroethylene.]
[N02BF01, gabapentin, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Gabapentin.]
[N06AB04, citalopram, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Citalopram.]
[C03DA05, finerenone, The therapeutic efficacy of Finerenone can be decreased when used in combination with Tapentadol.]
[R06AA04, clemastine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Clemastine.]
[M01AG01, mefenamic acid, The metabolism of Tapentadol can be decreased when combined with Mefenamic acid.]
[N06AX25, St. John's wort extract, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of St. John's Wort.]
[L03AB15, ropeginterferon alfa-2b, The risk or severity of neuropsychiatric effects can be increased when Ropeginterferon alfa-2b is combined with Tapentadol.]
[N01BB10, levobupivacaine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Levobupivacaine.]
[N06AA04, clomipramine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Clomipramine.]
[N03AE01, clonazepam, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Clonazepam.]
[S01EA04, clonidine, The risk or severity of sedation can be increased when Clonidine is combined with Tapentadol.]
[C03BA03, clopamide, The therapeutic efficacy of Clopamide can be decreased when used in combination with Tapentadol.]
[N05AH06, clothiapine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Clothiapine.]
[N05BA21, clotiazepam, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Clotiazepam.]
[A04AA01, ondansetron, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Ondansetron.]
[A04AA02, granisetron, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Granisetron.]
[N05AH02, clozapine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Clozapine.]
[N05BA13, halazepam, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Halazepam.]
[S02DA02, cocaine, The risk or severity of adverse effects can be increased when Cocaine is combined with Tapentadol.]
[C02KB01, metyrosine, Tapentadol may increase the sedative activities of Metyrosine.]
[R05DA04, codeine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Codeine.]
[M03AC05, hexafluorenium, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Hexafluronium.]
[A03AB10, hexocyclium, The risk or severity of adverse effects can be increased when Hexocyclium is combined with Tapentadol.]
[A03BB06, homatropine methylbromide, The risk or severity of adverse effects can be increased when Homatropine methylbromide is combined with Tapentadol.]
[N01AB07, desflurane, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Desflurane.]
[A04AA03, tropisetron, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Tropisetron.]
[C04AX28, ifenprodil, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Ifenprodil.]
[R06AX27, desloratadine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Desloratadine.]
[H01AX01, pegvisomant, The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Tapentadol.]
[N02CC05, almotriptan, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Almotriptan.]
[N05BA10, ketazolam, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Ketazolam.]
[A06AD12, lactitol, The therapeutic efficacy of Lactitol can be decreased when used in combination with Tapentadol.]
[N03AX09, lamotrigine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Lamotrigine.]
[S01GX02, levocabastine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Levocabastine.]
[N07BC04, lofexidine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Lofexidine.]
[N05CD06, lormetazepam, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Lormetazepam.]
[A06AD01, magnesium carbonate, The therapeutic efficacy of Magnesium carbonate can be decreased when used in combination with Tapentadol.]
[A03AA04, mebeverine, The risk or severity of adverse effects can be increased when Mebeverine is combined with Tapentadol.]
[N06AX13, medifoxamine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Medifoxamine.]
[N04AA03, methixene, The risk or severity of adverse effects can be increased when Metixene is combined with Tapentadol.]
[R03CB02, methoxyphenamine, Methoxyphenamine may increase the analgesic activities of Tapentadol.]
[R06AE03, cyclizine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Cyclizine.]
[N05CA10, cyclobarbital, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Cyclobarbital.]
[C03DA04, eplerenone, The therapeutic efficacy of Eplerenone can be decreased when used in combination with Tapentadol.]
[N05AD03, metylperon, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Melperone.]
[C03AA07, cyclopenthiazide, The therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Tapentadol.]
[N06AX07, minaprine, The risk or severity of adverse effects can be increased when Tapentadol is combined with Minaprine.]
[N06AG02, moclobemide, The risk or severity of adverse effects can be increased when Tapentadol is combined with Moclobemide.]
[R06AX02, cyproheptadine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Cyproheptadine.]
[C03XA02, conivaptan, The therapeutic efficacy of Conivaptan can be decreased when used in combination with Tapentadol.]
[M03CA01, dantrolene, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Dantrolene.]
[N06BX04, deanol, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Deanol.]
[A04AD11, nabilone, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Nabilone.]
[N07BB05, nalmefene, The therapeutic efficacy of Tapentadol can be decreased when used in combination with Nalmefene.]
[B05XA15, potassium lactate, The therapeutic efficacy of Potassium lactate can be decreased when used in combination with Tapentadol.]
[N05BA16, nordazepam, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Nordazepam.]
[N06AX06, nefazodone, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Nefazodone.]
[N05CM16, niaprazine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Niaprazine.]
[N03AG06, tiagabine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Tiagabine.]
[M03AC11, cisatracurium, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Cisatracurium.]
[R05DA06, normethadone, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Normethadone.]
[N06AB10, escitalopram, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Escitalopram.]
[G04BD08, solifenacin, The risk or severity of adverse effects can be increased when Solifenacin is combined with Tapentadol.]
[N06AA01, desipramine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Desipramine.]
[H01BA02, desmopressin, The risk or severity of hyponatremia can be increased when Tapentadol is combined with Desmopressin.]
[N03AF02, oxcarbazepine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Oxcarbazepine.]
[N06BX07, oxiracetam, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Oxiracetam.]
[N04AA08, dexetimide, The risk or severity of adverse effects can be increased when Dexetimide is combined with Tapentadol.]
[G04BD04, oxybutynin, The risk or severity of adverse effects can be increased when Oxybutynin is combined with Tapentadol.]
[A08AA04, dexfenfluramine, The risk or severity of serotonin syndrome can be increased when Dexfenfluramine is combined with Tapentadol.]
[A03AA01, oxyphencyclimine, The risk or severity of adverse effects can be increased when Oxyphencyclimine is combined with Tapentadol.]
[N06BA02, dextroamphetamine, Amphetamine may increase the analgesic activities of Tapentadol.]
[R05DA09, dextromethorphan, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Dextromethorphan.]
[N03AC01, paramethadione, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Paramethadione.]
[N02AC01, dextromoramide, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Dextromoramide.]
[N06AB05, paroxetine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Paroxetine.]
[B01AC04, clopidogrel, Tapentadol can cause a decrease in the absorption of Clopidogrel resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N07BC06, heroin, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Diamorphine.]
[N05BA01, diazepam, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Diazepam.]
[N03AX07, phenacemide, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Phenacemide.]
[N03AD02, phensuximide, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Phensuximide.]
[N06AA08, dibenzepin, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Dibenzepin.]
[S02DA04, dibucaine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Cinchocaine.]
[S01EC02, dichlorphenamide, The therapeutic efficacy of Diclofenamide can be decreased when used in combination with Tapentadol.]
[A03AA07, dicyclomine, The risk or severity of adverse effects can be increased when Dicyclomine is combined with Tapentadol.]
[N05AD05, pipamperone, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Pipamperone.]
[A03AB14, pipenzolate, The risk or severity of adverse effects can be increased when Pipenzolate is combined with Tapentadol.]
[C03CA03, piretanide, The therapeutic efficacy of Piretanide can be decreased when used in combination with Tapentadol.]
[A08AA03, diethylpropion, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Diethylpropion.]
[A03AB11, poldine, The risk or severity of adverse effects can be increased when Poldine is combined with Tapentadol.]
[N02BA11, diflunisal, The metabolism of Tapentadol can be decreased when combined with Diflunisal.]
[N02CA01, dihydroergotamine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Dihydroergotamine.]
[N02AA03, hydromorphone, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Hydromorphone.]
[D04AB07, pramoxine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Pramocaine.]
[R06AA11, dimenhydrinate, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Dimenhydrinate.]
[M03BX03, pridinol, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Pridinol.]
[R06AB03, dimethindene, The risk or severity of adverse effects can be increased when Dimetindene is combined with Tapentadol.]
[N03AG05, progabide, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Progabide.]
[R06AA02, diphenhydramine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Diphenhydramine.]
[A07DA01, diphenoxylate, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Diphenoxylate.]
[N05CD10, quazepam, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Quazepam.]
[N06BA11, dexmethylphenidate, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Dexmethylphenidate.]
[N06AA23, quinupramine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Quinupramine.]
[A03FA02, cisapride, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Cisapride.]
[N05AL04, remoxipride, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Remoxipride.]
[C01BA03, disopyramide, The risk or severity of adverse effects can be increased when Disopyramide is combined with Tapentadol.]
[N07XX02, riluzole, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Riluzole.]
[N05AX08, risperidone, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Risperidone.]
[R06AE09, levocetirizine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Levocetirizine.]
[N01BB09, ropivacaine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Ropivacaine.]
[C03XA01, tolvaptan, The therapeutic efficacy of Tolvaptan can be decreased when used in combination with Tapentadol.]
[N06AA16, dothiepin, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Dosulepin.]
[N06AA12, doxepin, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[A06AB06, sennosides, USP, The therapeutic efficacy of Sennosides can be decreased when used in combination with Tapentadol.]
[R06AA09, doxylamine, Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Tapentadol.]
[N06AB06, sertraline, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Sertraline.]
[N01AB08, sevoflurane, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Sevoflurane.]
[N05AD08, droperidol, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Droperidol.]
[A08AA10, sibutramine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Sibutramine.]
[V03AG05, sodium phosphate, The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Tapentadol.]
[A12CA02, sodium sulfate, The therapeutic efficacy of Sodium sulfate can be decreased when used in combination with Tapentadol.]
[N05AL02, sultopride, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Sultopride.]
[N02CC01, sumatriptan, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Sumatriptan.]
[M03BX07, tetrazepam, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Tetrazepam.]
[M03BX05, thiocolchicoside, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Thiocolchicoside.]
[N05AB05, thiopropazate, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Thiopropazate.]
[G04BD01, emepronium, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Emepronium.]
[N06AX14, tianeptine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Tianeptine.]
[N05BA23, tofisopam, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Tofisopam.]
[N06AG03, toloxatone, The risk or severity of adverse effects can be increased when Tapentadol is combined with Toloxatone.]
[N03AX11, topiramate, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Topiramate.]
[C03CA04, torsemide, The therapeutic efficacy of Torasemide can be decreased when used in combination with Tapentadol.]
[N05CD11, triazulenone, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Loprazolam.]
[N05CC01, chloral hydrate, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Chloral hydrate.]
[N05CM07, triclofos, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Triclofos.]
[A03AB08, tridihexethyl, The risk or severity of adverse effects can be increased when Tridihexethyl is combined with Tapentadol.]
[R06AA10, trimethobenzamide, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Trimethobenzamide.]
[N04AA12, tropatepine, The risk or severity of adverse effects can be increased when Tropatepine is combined with Tapentadol.]
[N01AB04, enflurane, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Enflurane.]
[C02CA06, urapidil, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Urapidil.]
[N05AL06, veralipride, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Veralipride.]
[S01GX10, epinastine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Epinastine.]
[N06AX16, venlafaxine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Venlafaxine.]
[N05CF02, zolpidem, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.]
[N03AX15, zonisamide, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Zonisamide.]
[N05CF01, zopiclone, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Zopiclone.]
[N05AX11, zotepine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Zotepine.]
[C02AC02, guanfacine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Guanfacine.]
[C01BG01, moricizine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Moricizine.]
[G02AB03, ergonovine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Ergometrine.]
[C04AE01, ergoloid mesylates, USP, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Ergoloid mesylate.]
[N02CA02, ergotamine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Ergotamine.]
[N03AG01, valproic acid, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Valproic acid.]
[N05CD04, estazolam, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Estazolam.]
[C01CA15, gepefrine, Gepefrine may increase the analgesic activities of Tapentadol.]
[N05CM08, ethchlorvynol, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Ethchlorvynol.]
[N04AA05, profenamine, The risk or severity of adverse effects can be increased when Profenamine is combined with Tapentadol.]
[N03AD01, ethosuximide, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Ethosuximide.]
[N03AB01, ethotoin, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Ethotoin.]
[S01XA06, ethylmorphine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Ethylmorphine.]
[N01AX07, etomidate, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Etomidate.]
[N05AE03, sertindole, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Sertindole.]
[R06AX12, terfenadine, The risk or severity of adverse effects can be increased when Terfenadine is combined with Tapentadol.]
[N06AX12, bupropion, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Bupropion.]
[N06AB08, fluvoxamine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Fluvoxamine.]
[A05AA01, chenodeoxycholic acid, The metabolism of Tapentadol can be decreased when combined with Chenodeoxycholic acid.]
[N03AX26, fenfluramine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Fenfluramine.]
[R03CC04, fenoterol, The risk or severity of adverse effects can be increased when Fenoterol is combined with Tapentadol.]
[N02AB03, fentanyl, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Fentanyl.]
[G04BD02, flavoxate, The risk or severity of adverse effects can be increased when Flavoxate is combined with Tapentadol.]
[N07CA03, flunarizine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Flunarizine.]
[N05CD03, flunitrazepam, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Flunitrazepam.]
[N06AA14, melitracen, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Melitracen.]
[V03AZ01, ethanol, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Ethanol.]
[N06AB03, fluoxetine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[N05AF01, flupenthixol, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[N05AB02, fluphenazine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Fluphenazine.]
[N05CD01, flurazepam, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Flurazepam.]
[N05AG01, fluspirilene, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Fluspirilene.]
[M03AA01, alcuronium, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Alcuronium.]
[G01AX06, furazolidone, The risk or severity of adverse effects can be increased when Tapentadol is combined with Furazolidone.]
[C03CA01, furosemide, The therapeutic efficacy of Furosemide can be decreased when used in combination with Tapentadol.]
[N05CF04, eszopiclone, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Eszopiclone.]
[N05AL05, amisulpride, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Amisulpride.]
[M03AC02, gallamine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Gallamine.]
[N03AA04, barbexaclone, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Barbexaclone.]
[N06AX08, bifemelane, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Bifemelane.]
[N04BC06, cabergoline, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Cabergoline.]
[N03AD03, methsuximide, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Methsuximide.]
[N01AH02, alfentanil, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Alfentanil.]
[A06AH02, alvimopan, The risk or severity of adverse effects can be increased when Tapentadol is combined with Alvimopan.]
[N05CM18, dexmedetomidine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Dexmedetomidine.]
[N05CE01, glutethimide, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Glutethimide.]
[A06AX01, glycerin, The therapeutic efficacy of Glycerin can be decreased when used in combination with Tapentadol.]
[L01EX02, sorafenib, The metabolism of Tapentadol can be decreased when combined with Sorafenib.]
[B01AA12, fluindione, The risk or severity of adverse effects can be increased when Tapentadol is combined with Fluindione.]
[N05AD01, haloperidol, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Haloperidol.]
[N01AB01, halothane, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Halothane.]
[N05AH04, quetiapine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Quetiapine.]
[N02CX03, iprazochrome, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Iprazochrome.]
[N05CA21, allobarbital, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Allobarbital.]
[B05CB03, magnesium citrate, The therapeutic efficacy of Magnesium citrate can be decreased when used in combination with Tapentadol.]
[A12CD02, sodium monofluorophosphate, The therapeutic efficacy of Sodium fluorophosphate can be decreased when used in combination with Tapentadol.]
[N05CA16, hexobarbital, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Hexobarbital.]
[C03AA03, hydrochlorothiazide, The therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Tapentadol.]
[R05DA03, hydrocodone, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.]
[C03AA02, hydroflumethiazide, The therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Tapentadol.]
[A12BA02, potassium citrate, The therapeutic efficacy of Potassium citrate can be decreased when used in combination with Tapentadol.]
[G04BD06, propiverine, The risk or severity of adverse effects can be increased when Propiverine is combined with Tapentadol.]
[N05AX07, prothipendyl, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Prothipendyl.]
[N05BB01, hydroxyzine, Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Tapentadol.]
[A06AD21, sodium tartrate, The therapeutic efficacy of Sodium tartrate can be decreased when used in combination with Tapentadol.]
[N01AH03, sufentanil, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Sufentanil.]
[N06AA02, imipramine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Imipramine.]
[M03BX02, tizanidine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Tizanidine.]
[C03BA11, indapamide, The therapeutic efficacy of Indapamide can be decreased when used in combination with Tapentadol.]
[S01BC01, indomethacin, The metabolism of Tapentadol can be decreased when combined with Indomethacin.]
[N06AX17, milnacipran, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Milnacipran.]
[A03AA30, piperidolate, The risk or severity of adverse effects can be increased when Piperidolate is combined with Tapentadol.]
[N01BB08, articaine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Articaine.]
[N05BA12, alprazolam, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Alprazolam.]
[N05CH02, ramelteon, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Ramelteon.]
[R06AE01, buclizine, The risk or severity of adverse effects can be increased when Buclizine is combined with Tapentadol.]
[C07AA01, alprenolol, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Alprenolol.]
[C03BA02, quinethazone, The therapeutic efficacy of Quinethazone can be decreased when used in combination with Tapentadol.]
[N06AA13, iprindole, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Iprindole.]
[N06AF05, iproniazid, The risk or severity of adverse effects can be increased when Tapentadol is combined with Iproniazid.]
[N05AA07, chlorproethazine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Chlorproethazine.]
[N06AF01, isocarboxazid, The risk or severity of adverse effects can be increased when Tapentadol is combined with Isocarboxazid.]
[N01AB06, isoflurane, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Isoflurane.]
[N04BX02, entacapone, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Entacapone.]
[J04AC01, isoniazid, The risk or severity of serotonin syndrome can be increased when Isoniazid is combined with Tapentadol.]
[N06AX18, reboxetine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Reboxetine.]
[N01AX03, ketamine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Ketamine.]
[C02KD01, ketanserin, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Ketanserin.]
[J02AB02, ketoconazole, The metabolism of Tapentadol can be decreased when combined with Ketoconazole.]
[N05AH03, olanzapine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Olanzapine.]
[V03AC03, deferasirox, The metabolism of Tapentadol can be decreased when combined with Deferasirox.]
[N04BC09, rotigotine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Rotigotine.]
[N04BB01, amantadine, The risk or severity of adverse effects can be increased when Amantadine is combined with Tapentadol.]
[A06AD11, lactulose, The therapeutic efficacy of Lactulose can be decreased when used in combination with Tapentadol.]
[A06AX03, lubiprostone, The therapeutic efficacy of Lubiprostone can be decreased when used in combination with Tapentadol.]
[N03AX18, lacosamide, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Lacosamide.]
[C03CC01, ethacrynic acid, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Tapentadol.]
[N04BA01, levodopa, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Levodopa.]
[S02DA01, lidocaine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Lidocaine.]
[C03DB01, amiloride, The therapeutic efficacy of Amiloride can be decreased when used in combination with Tapentadol.]
[N02CA07, lisuride, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Lisuride.]
[N06AA07, lofepramine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Lofepramine.]
[N05BA06, lorazepam, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Lorazepam.]
[N05AH01, loxapine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Loxapine.]
[G04BX01, magnesium hydroxide, The therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Tapentadol.]
[A12CC10, magnesium oxide, The therapeutic efficacy of Magnesium oxide can be decreased when used in combination with Tapentadol.]
[V04CC02, magnesium sulfate, The therapeutic efficacy of Tapentadol can be increased when used in combination with Magnesium sulfate.]
[V04CX04, mannitol, The therapeutic efficacy of Mannitol can be decreased when used in combination with Tapentadol.]
[N06AA21, maprotiline, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.]
[A08AA05, mazindol, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Mazindol.]
[C02BB01, mecamylamine, The risk or severity of adverse effects can be increased when Mecamylamine is combined with Tapentadol.]
[R06AE05, meclizine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Meclizine.]
[N05BA03, medazepam, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Medazepam.]
[A06AB07, cascara sagrada, The therapeutic efficacy of Frangula purshiana bark can be decreased when used in combination with Tapentadol.]
[C03BA05, mefruside, The therapeutic efficacy of Mefruside can be decreased when used in combination with Tapentadol.]
[N05CH01, melatonin, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Melatonin.]
[N02AB02, meperidine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Meperidine.]
[C01CA11, mephentermine, Mephentermine may increase the analgesic activities of Tapentadol.]
[N03AB04, mephenytoin, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Mephenytoin.]
[N03AA01, mephobarbital, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Methylphenobarbital.]
[N01BB03, mepivacaine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Mepivacaine.]
[N05BC01, meprobamate, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Meprobamate.]
[N02AX05, meptazinol, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Meptazinol.]
[C03BC01, mersalyl, The therapeutic efficacy of Mersalyl can be decreased when used in combination with Tapentadol.]
[N05AC03, mesoridazine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Mesoridazine.]
[N05AX13, paliperidone, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Paliperidone.]
[A04AA04, dolasetron, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Dolasetron.]
[N07BC02, methadone, The risk or severity of adverse effects can be increased when Methadone is combined with Tapentadol.]
[N06BA03, methamphetamine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Metamfetamine.]
[A03AB07, methantheline, The risk or severity of adverse effects can be increased when Methantheline is combined with Tapentadol.]
[R06AC05, methapyrilene, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Methapyrilene.]
[N05CM01, methaqualone, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Methaqualone.]
[N03AA30, metharbital, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Metharbital.]
[S01EC05, methazolamide, The therapeutic efficacy of Methazolamide can be decreased when used in combination with Tapentadol.]
[G02CB05, metergoline, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Metergoline.]
[M03BA03, methocarbamol, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Methocarbamol.]
[N05CA15, methohexital, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Methohexital.]
[N02BG08, ziconotide, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Ziconotide.]
[N05AA02, methotrimeprazine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N02BG09, methoxyflurane, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Methoxyflurane.]
[C03AA08, methyclothiazide, The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Tapentadol.]
[A06AC06, methylcellulose, The therapeutic efficacy of Methylcellulose can be decreased when used in combination with Tapentadol.]
[V04CG05, methylene blue, Tapentadol may increase the serotonergic activities of Methylene blue.]
[N03AF03, rufinamide, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Rufinamide.]
[N05CE02, methyprylon, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Methyprylon.]
[N02CA04, methysergide, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Methysergide.]
[A03FA01, metoclopramide, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Tapentadol.]
[C03BA08, metolazone, The therapeutic efficacy of Metolazone can be decreased when used in combination with Tapentadol.]
[N06AX03, mianserin, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Mianserin.]
[N05CD08, midazolam, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Midazolam.]
[A06AA01, mineral oil, The therapeutic efficacy of Mineral oil can be decreased when used in combination with Tapentadol.]
[J01AA08, minocycline, Minocycline may increase the central nervous system depressant (CNS depressant) activities of Tapentadol.]
[N06BA12, lisdexamfetamine, Lisdexamfetamine may increase the analgesic activities of Tapentadol.]
[N05AE02, molindone, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Molindone.]
[N06AA09, amitriptyline, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Amitriptyline.]
[N02AA01, morphine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Morphine.]
[A04AA05, palonosetron, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Palonosetron.]
[B02BX05, eltrombopag, The metabolism of Tapentadol can be decreased when combined with Eltrombopag.]
[M03AC03, vecuronium, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Vecuronium.]
[N05CA02, amobarbital, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Amobarbital.]
[R03BB01, ipratropium bromide, The risk or severity of adverse effects can be increased when Ipratropium is combined with Tapentadol.]
[N06AA17, amoxapine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Amoxapine.]
[N03AB05, fosphenytoin, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Fosphenytoin.]
[N04BC04, ropinirole, Tapentadol may increase the sedative activities of Ropinirole.]
[C04AX21, nafronyl, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Naftidrofuryl.]
[N02AF02, nalbuphine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Nalbuphine.]
[V03AB15, naloxone, The therapeutic efficacy of Tapentadol can be decreased when used in combination with Naloxone.]
[N07BB04, naltrexone, The risk or severity of adverse effects can be increased when Naltrexone is combined with Tapentadol.]
[S01GA01, naphazoline, Naphazoline may increase the central nervous system depressant (CNS depressant) activities of Tapentadol.]
[N06BA01, amphetamine, Amphetamine may increase the analgesic activities of Tapentadol.]
[N06AX21, duloxetine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Duloxetine.]
[N04BX01, tolcapone, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Tolcapone.]
[N01AH06, remifentanil, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Remifentanil.]
[N05AX14, iloperidone, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Iloperidone.]
[N06AX23, desvenlafaxine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Desvenlafaxine.]
[N06AF02, nialamide, The risk or severity of adverse effects can be increased when Tapentadol is combined with Nialamide.]
[C08CA04, nicardipine, The risk or severity of adverse effects can be increased when Nicardipine is combined with Tapentadol.]
[M02AA17, niflumic acid, The metabolism of Tapentadol can be decreased when combined with Niflumic acid.]
[N05CD02, nitrazepam, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Nitrazepam.]
[N05CF03, zaleplon, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Zaleplon.]
[N04BC05, pramipexole, Tapentadol may increase the sedative activities of Pramipexole.]
[N01AX13, nitrous oxide, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Nitrous oxide.]
[N06AX04, nomifensine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Nomifensine.]
[N06AA10, nortriptyline, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Nortriptyline.]
[N06AA05, opipramol, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Opipramol.]
[N02AA02, opium, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Opium.]
[N05BA04, oxazepam, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Oxazepam.]
[C07AA02, oxprenolol, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Oxprenolol.]
[N02AA05, oxycodone, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Oxycodone.]
[N02AA11, oxymorphone, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Oxymorphone.]
[N05AE01, oxypertine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Oxypertine.]
[A03AB03, oxyphenonium, The risk or severity of adverse effects can be increased when Oxyphenonium is combined with Tapentadol.]
[N05AH05, asenapine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Asenapine.]
[N07XX04, sodium oxybate, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.]
[M03AC01, pancuronium, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Pancuronium.]
[N05CC05, paraldehyde, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.]
[C02KC01, pargyline, The risk or severity of adverse effects can be increased when Tapentadol is combined with Pargyline.]
[G04BD11, fesoterodine, The risk or severity of adverse effects can be increased when Fesoterodine is combined with Tapentadol.]
[C07AA23, penbutolol, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Penbutolol.]
[N05AG03, penfluridol, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Penfluridol.]
[N02AD01, pentazocine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Pentazocine.]
[N05CA01, pentobarbital, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Pentobarbital.]
[N05AB10, perazine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Perazine.]
[N04BC02, pergolide, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Pergolide.]
[N05AB03, perphenazine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Perphenazine.]
[N02AD02, phenazocine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Phenazocine.]
[N06AF03, phenelzine, The risk or severity of adverse effects can be increased when Tapentadol is combined with Phenelzine.]
[B01AA02, phenindione, The risk or severity of adverse effects can be increased when Tapentadol is combined with Phenindione.]
[N03AA02, phenobarbital, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Phenobarbital.]
[A06AB01, oxyphenisatin, The therapeutic efficacy of Oxyphenisatin can be decreased when used in combination with Tapentadol.]
[N01AH04, phenoperidine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Phenoperidine.]
[B01AA04, phenprocoumon, The risk or severity of adverse effects can be increased when Tapentadol is combined with Phenprocoumon.]
[A08AA01, phentermine, Phentermine may increase the analgesic activities of Tapentadol.]
[N03AB02, phenytoin, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Phenytoin.]
[N05AG02, pimozide, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Pimozide.]
[C07AA03, pindolol, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Pindolol.]
[N05AC04, pipothiazine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Pipotiazine.]
[A02BX03, pirenzepine, The risk or severity of adverse effects can be increased when Pirenzepine is combined with Tapentadol.]
[N02AC03, pirinitramide, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Piritramide.]
[N02CX01, pizotyline, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Pizotifen.]
[N05CA22, proxibarbal, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Proxibarbal.]
[A06AD15, polyethylene glycols, The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Tapentadol.]
[A03AE01, alosetron, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Alosetron.]
[C03AA05, polythiazide, The therapeutic efficacy of Polythiazide can be decreased when used in combination with Tapentadol.]
[N05BA11, prazepam, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Prazepam.]
[N01BB04, prilocaine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Prilocaine.]
[N03AA03, primidone, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Primidone.]
[S01HA05, procaine, The risk or severity of adverse effects can be increased when Tapentadol is combined with Procaine.]
[L01XB01, procarbazine, The risk or severity of adverse effects can be increased when Tapentadol is combined with Procarbazine.]
[N05AB04, prochlorperazine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Prochlorperazine.]
[N04AA04, procyclidine, The risk or severity of adverse effects can be increased when Procyclidine is combined with Tapentadol.]
[N05AA03, promazine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Promazine.]
[R06AD02, promethazine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Promethazine.]
[N01AX04, propanidid, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Propanidid.]
[A03AB05, propantheline, The risk or severity of adverse effects can be increased when Propantheline is combined with Tapentadol.]
[N05AC01, periciazine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Periciazine.]
[N05CM06, propiomazine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Propiomazine.]
[N01AX10, propofol, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Propofol.]
[N02AC04, propoxyphene, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Dextropropoxyphene.]
[N02CC04, rizatriptan, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Rizatriptan.]
[N06AA11, protriptyline, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Protriptyline.]
[R01BA02, pseudoephedrine, Pseudoephedrine may increase the analgesic activities of Tapentadol.]
[N05AX12, aripiprazole, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.]
[A03AB15, diphemanil, The risk or severity of adverse effects can be increased when Diphemanil is combined with Tapentadol.]
[A03AB09, isopropamide, The risk or severity of adverse effects can be increased when Isopropamide is combined with Tapentadol.]
[S01FA03, methscopolamine, The risk or severity of adverse effects can be increased when Methscopolamine is combined with Tapentadol.]
[N05CA07, talbutal, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Talbutal.]
[N05CA09, vinbarbital, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Vinbarbital.]
[N05BB02, captodiamine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Captodiame.]
[M03BA04, styramate, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Styramate.]
[P02CC01, pyrantel, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Pyrantel.]
[R06AC01, pyrilamine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Mepyramine.]
[C01BA01, quinidine, The risk or severity of adverse effects can be increased when Quinidine is combined with Tapentadol.]
[P01BC01, quinine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Quinine.]
[C02AA02, reserpine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Reserpine.]
[J04AB02, rifampin, The metabolism of Tapentadol can be decreased when combined with Rifampicin.]
[N06AX01, 5-hydroxytryptophan, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Oxitriptan.]
[S01FA02, scopolamine, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05CA06, secobarbital, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Secobarbital.]
[N04BD01, selegiline, The risk or severity of adverse effects can be increased when Tapentadol is combined with Selegiline.]
[V04CC01, sorbitol, The therapeutic efficacy of Sorbitol can be decreased when used in combination with Tapentadol.]
[C03DA01, spironolactone, The therapeutic efficacy of Spironolactone can be decreased when used in combination with Tapentadol.]
[N06AF04, tranylcypromine, Narcotic analgesics - monoamine oxidase (MAO) inhibitors]
[N06AF01, isocarboxazid, Narcotic analgesics - monoamine oxidase (MAO) inhibitors]
[N06AF03, phenelzine, Narcotic analgesics - monoamine oxidase (MAO) inhibitors]
[L01XB01, procarbazine, Narcotic analgesics - monoamine oxidase (MAO) inhibitors]
[N04BD01, selegiline, Narcotic analgesics - monoamine oxidase (MAO) inhibitors]
